文献速递肾小球疾病

尿白介素-6升高可预测IgA肾病进展

Elevated Urinary IL-6 Predicts the Progression of IgA Nephropathy.
PubMed 文献 · Kidney Int Rep · 2022-12-28

该研究先以细胞因子抗体芯片在32例IgA肾病患者和16例健康对照中筛选标志物,并在222例患者和159例匹配对照的多中心队列中验证;尿白介素-6和转化生长因子-β1区分效能好,AUC为0.9725。在762例中位随访65个月的患者中,尿白介素-6升高与复合肾脏结局高风险独立相关(每log转换IL-6的HR为1.420 [1.139-1.769])。

要点

  • 尿白介素-6和转化生长因子-β1可较好区分IgA肾病患者与健康对照,AUC为0.9725。
  • 尿白介素-6升高与复合肾脏结局高风险独立相关,每log转换IL-6的HR为1.420。
  • 校正多个混杂因素后,尿转化生长因子-β1与IgA肾病进展无统计学显著关联。

核心结论

  • 尿白介素-6和转化生长因子-β1水平升高可预测IgA肾病进展;尿白介素-6是独立危险因素和有前景的无创预测指标。

研究设计与样本

  • 研究采用细胞因子抗体芯片检测32例IgA肾病患者和16例健康对照的血清及尿液中9种常见细胞因子,这些细胞因子选自23种IgA肾病相关标志物。
  • 在222例IgA肾病患者和159例年龄、性别匹配的健康对照的多中心队列中验证最佳标志物。
  • 在762例IgA肾病患者中进一步探讨标志物与IgA肾病进展的关联,中位随访65个月。

主要发现

  • 在9种候选标志物中,尿白介素-6和转化生长因子-β1水平区分IgA肾病患者与健康对照最佳。
  • 在诊断队列中,IgA肾病患者尿白介素-6和转化生长因子-β1水平均升高,区分效能好,AUC为0.9725(95%置信区间:0.9593-0.9858)。
  • 尿白介素-6水平升高与复合肾脏结局高风险独立且显著相关(每log转换IL-6的风险比为1.420 [1.139-1.769])。
  • 校正多个混杂因素后,尿转化生长因子-β1水平与IgA肾病进展之间未观察到统计学显著性。

关键数值与推荐

  • 尿白介素-6和转化生长因子-β1区分IgA肾病患者与健康对照的AUC为0.9725(95%置信区间:0.9593-0.9858)。
  • 尿白介素-6每log转换与复合肾脏结局的风险比为1.420(95%置信区间:1.139-1.769)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Immunoglobulin A nephropathy (IgAN) is the most common glomerulonephritis worldwide. However, biomarkers for predicting the progression or regression of IgAN remain a clinical challenge. In the present study, we aim to identify promising prognostic markers of IgAN. METHODS: Using the cytokine antibody array, we detected serum and urinary levels of 9 common cytokines selected from 23 IgAN-related biomarkers in 32 patients with IgAN and 16 healthy controls. The best biomarkers for distinguishing IgAN patients from healthy controls were identified and confirmed in a multicenter cohort with 222 patients with IgAN and 159 age- and sex-matched healthy controls. Their associations with IgAN progression were further explored in 762 patients with IgAN with a median follow-up of 65 months. RESULTS: Among the 9 candidate markers, urinary interleukin-6 (IL-6) and transforming growth factor-β1 (TGF-β1) levels were the best for distinguishing patients with IgAN from healthy controls. In the diagnostic cohort, both urinary IL-6 and TGF-β1 levels were elevated in patients with IgAN and showed good discriminatory power, with an area under curve (AUC) of 0.9725 (95% confidence interval: 0.9593-0.9858). Elevated urinary IL-6 level was independently and significantly correlated with the high risk of composite renal outcome (hazard ratio per log-transformed IL-6:1.420 [1.139-1.769]), but no statistical significance was observed between urinary TGF-β1 level and IgAN progression after adjusting for multiple confounders. CONCLUSIONS: Elevated urinary IL-6 and TGF-β1 levels predict the progression of IgAN. Urinary IL-6 is an independent risk factor and a promising noninvasive predictor for IgAN progression.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Zhao W, Feng S, Wang Y, et al. Elevated Urinary IL-6 Predicts the Progression of IgA Nephropathy. Kidney Int Rep. 2022. PMID: 36938089. doi:10.1016/j.ekir.2022.12.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。